Shots:
- GSK to acquire IDRx incl. its lead candidate IDRX-42, for $1B upfront & ~$150M in regulatory milestones (total ~$1.15B). It will also pay success-based milestones & tiered royalties to Merck KGaA for IDRX-42
- IDRX-42 (TKI, small molecule) targets key KIT mutations, responsible for proliferation & survival of tumor cells, & is under P-I/Ib (StrateGIST 1) trial for 1L & 2L treatment of greater GIST & KIT mutated patients. GSK will expedite the development this year
- The study showed ORR of 29% (n=87, incl. 1 CR & 24 PRs) in efficacy-evaluable 2L patients & 53% (n=15, incl. 1 CR & 7PRs) in those who received 1L therapy; 2 PRs were awaiting verification at the cut off. Safety was favorable, with data highlighted at CTOS 2024
Ref: GSK | Image: IDRx
Related News:- GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
